PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	04725697.9
	Filing Date	05-Apr-2004
	First Named Inventor	Giorgio BONANOMI
	Title	COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PB60172

I hereby appoint:	- ···	
E Practitioners associated with the Customer Numbers.	23347	
Or	23347	
☐ Practitioner(s) named below:		
Name		Registration Number
As my/our attorney(s) or agent(s) to prosecute the application i	dentified above, and to trans	act all business in the
United States Patent and Trademark Office connected therewith	1.	
Please recognize or change the correspondence address for the		to:
The address associated with the above-mentioned Custome Or	r Number:	
Or The address associated with Customer Number 23347		
Or		
☐ Firm or Individual Name:		
Address:		
Address:		
City:	State:	Zip:
Country:		
Telephone:	Fax:	
I am the: ☐ Applicant/Inventor:		
Assignee or record of the entire interest. See 37 CFR	2.71	
Statement under ALCFR 3.73(b) is enclosed. (Form P		
	pplicant or Assignee of Rec	rord
Signature:	Date:	
Name: Peter John GIDDINGS	Telephone: +44 20 8047 4414	
Title and Company: Attorney and Authorised Official, Glax		
NOTE: Signatures of all the inventors or assignees of record or		epresentative(s) are required.
Submit multiple forms if more than one signature is required, so		
□ *Total of: forms are submitted.		

forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1456

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

Approved for use infougn 11/30/2003. OTTHE GOSTAGE U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CRF 3.73(b)

Applicant/Patent Owner: Glaxo Group Limited			
International Application No./Patent No PCT/EP2004/003678 Filed/Issue Date: 05-Apr-2004			
Entitled: COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF			
Glaxo Group Limited, a corporation, states that it is:			
1. Ethe assignee of the entire right, title, and interest; or			
2. an assignee of less than the entire right, title and interest.			
The extent (by percentage) of its ownership interest is% in the patent application/patent identified above			
by virtue of either;			
A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was			
recorded in the United States Patent and Trademark Office at Reel, Frame, or for which copy thereof is attached.			
OR			
OK .			
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee			
as shown below:			
The document was recorded in the United States Patent and Trademark Office at			
Reel , Frame , or for which a copy thereof is attached.			
2. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel, Frame, or for which a copy thereof is attached.			
3. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel , Frame , or for which a copy thereof is attached.			
[] Additional documents in the chain of title are listed on a supplemental sheet.			
[X] Copies of assignments or other documents in the chain of title are attached.			
[NOTE: A separate copy (i.e., a true cop y of the original assignment document(s)) must be submitted to Assignment			
Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.			
See MPEP 302.08]			
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.			
/_J X			
Signature			
Signature P			
Peter John GIDDINGS +44 20 8047 4414			
Printed or Typed Name Telephone Number			
Attorney and Authorised Official			
Title			

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM S TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS I/WE, Giorgio BONANOMI, Dieter HAMPRECHT, Fabrizio MICHELI and Silvia TERRENI, of GlaxoSmithKline SpA of Via Alessandro Fleming 2, 37135 Verona, Italy (hereinafter called "the inventor(s)") have invented or discovered "COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF" (hereinafter called "the invention") for which a patent application No. 0308025.6 was filed on 7 April 2003 in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT Aplication No. PCT/EP2004/003678 filed 5 April 2004)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SpA, a company incorporated in Italy whose registered address is Via Alessandro Fleming 2, 37100 Verona, Italy, and

GLAXOSMITHKLINE SpA have authorised and requested my/our making the application, and

WHEREAS GLAXO GROUP LIMITED a company incorporated in England and Wales whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England, is desirous of acquiring from GLAXOSMITHKLINE SpA the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SpA of the invention and the application and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the o:\ipd\ms\USASSI

law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SpA and GLAXOSMITHKLINE SpA in turn hereby assigns and transfers to GLAXO GROUP LIMITED its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE SpA hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO GROUP LIMITED.

AND GLAXOSMITHKLINE SpA hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXO GROUP LIMITED, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 7 April 2003 the inventor(s) and **Peter John GIDDINGS** as Attorney of **GLAXOSMITHKLINE SpA** by virtue of a Power of Attorney granted by **GLAXOSMITHKLINE SpA** have hereunto set their respective hands.

SIGNED by Giorgio BONANOMI:

Date: <u>13/09</u>(05

SIGNED by Dieter HAMPRECHT:

Date: 28/09/05

o:\ipd\ms\USASS1

SIGNED by Fabrizio MICHELI:

SIGNED by Silvia TERRENI:

SIGNED by Peter John GIDDINGS

as the Attorney of

GLAXOSMITHKLINE SPA

Date: 13-09.05

Date: 20/09/05

Date: ______\$007 130 []

o:\ipd\ms\USASS1